摘要
肝细胞性肝癌(肝癌hepatocellular carcinoma,HCC)发病率高,治疗难度高,预后差,需多学科、多种手段联合治疗。肝癌的根治性治疗措施包括手术切除、肝移植、介入治疗、射频消融、免疫治疗等。近年来,以索拉非尼为代表的分子靶向药物的问世开拓了肝癌治疗的新局面,该文就近年来有关索拉非尼在肝癌外科综合治疗的相关研究行分类分析,以指导其在临床的应用。
The HCC( hepatocellular carcinoma,HCC) has high incidence,treatment of intractable,and the prognosis is poor,lt needs combined therapy. The radical treatment including surgical resection,liver transplantation, TACE,radiofrequency,ablation,immunotherapy and so on. In recent years with sorafenib as a representative of the molecular targeted drugs shows significant curative effect in treating HCC. This review aims to collecting the latest related researches about sorafenib in HCC in recent years,and carries on the classified analysis,in order to have a comprehensive understanding to guide its clinical application.
出处
《外科研究与新技术》
2013年第4期229-231,共3页
Surgical Research and New Technique
